Sofia N. Verouti

Dr. Sofia N. Verouti

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
SVSofia N. Verouti
Sofia N. Verouti
EBEmilie Boscardin
Emilie Boscardin
EHEdith Hummler
Edith Hummler
SFSimona Frateschi
Simona Frateschi

22 August 2018 in The Analyst
Verified
Journal Article
Closed access
PDF file
ABAndrea Bileck
Andrea Bileck
SVSofia N. Verouti
Sofia N. Verouti
GEGeneviève Escher
Geneviève Escher
BVBruno Vogt
Bruno Vogt
MGMichael Groessl
Michael Groessl
Steroids are key players in a high variety of physiological processes and are typically analyzed for the diagnosis of hormonal disorders.

18 January 2013 in The International Journal of Artificial Organs
Verified
Journal Article
Closed access
SVSofia N. Verouti
Sofia N. Verouti
Alexandros TsouprasAlexandros Tsoupras
Alexandros Tsoupras
FAFotini Alevizopoulou
Fotini Alevizopoulou
CDConstantinos A. Demopoulos
Constantinos A. Demopoulos
CIChristos Iatrou
Christos Iatrou
Purpose: Paricalcitol improves the inflammatory status of hemodialysis patients. PAF is a strong inflammatory mediator which is produced during hemodialysis. We studied the effects of paricalcitol on PAF and other inflammatory mediators implicated in chronic kidney disease (CKD). Methods: We examined the in vitro effects of paricalcitol on PAF/thrombin-induced aggregation as well as on the activities of PAF-basic metabolic enzymes, lyso-PAF acetyltransferase (Lyso-PAF-AT), DTT-insensitive CDP-choline: 1-alkyl-2-acetyl-sn-glycerol cholinephospho-transferase (PAF-CPT) and PAF-acetylhydrolase (PAF-AH) in blood cells from healthy volunteers. In addition, the in vivo effects of paricalcitol on the above these enzymes were examined in plasma and blood cells of hemodialysis patients who had not received any type of vitamin D treatment during the last three months before and after receiving paricalcitol for a month. Finally, IL-12p70, IL-1β, IL-6, IL-8 and TNF-α were measured. Results: Paricalcitol inhibited in vitro PAF/thrombin-induced platelet aggregation and the inhibitory effect was comparable with that of PAF/thrombin antagonists. In addition, paricalcitol inhibited in vitro PAF-CPT activity in platelets and leukocytes and increased PAF-AH activity in leukocytes, while much higher concentrations of paricalcitol were needed to inhibit Lyso-PAF-AT activity. Similarly, in hemodialysis patients, paricalcitol treatment reduced PAF-CPT activity in platelets and leukocytes and increased PAF-AH activity in leukocytes, while it could not influence Lyso-PAF-AT activity. On the other hand, paricalcitol therapy reduced IL-8, IL-1β, and TNF-α. Conclusions: These results further support the beneficial effects of vitamin D treatment in hemodialysis patients, since it strongly affects PAF/thrombin activities, PAF-metabolism, and IL-8, IL-1β and TNF-α circulating levels.

14 August 2019 in Frontiers in Physiology
Verified
Journal Article
Open access
JCJérémie Canonica
Jérémie Canonica
SFSimona Frateschi
Simona Frateschi
EBEmilie Boscardin
Emilie Boscardin
AEAnna Ebering
Anna Ebering
CSChloé Sergi
Chloé Sergi
EHEdith Hummler
Edith Hummler
Chronic glucocorticoid infusion impairs NCC activity and induces a non-dipping profile in mice, suggesting that glucocorticoids are essential for daily blood pressure variations. In this paper, we studied mice lacking the renal tubular glucocorticoid receptor (GR) in adulthood (GR knockouts, Nr3c1Pax8/LC1). Upon standard salt diet, Nr3c1Pax8/LC1 mice grow normally, but show reduced NCC activity despite normal plasma aldosterone levels. Following diet switch to low sodium, Nr3c1Pax8/LC1 mice exhibit a transient but significant reduction in the activity of NCC and expression of NHE3 and NKCC2 accompanied by significant increased Spak activity. This is followed by transiently increased urinary sodium excretion and higher plasma aldosterone concentrations. Plasma corticosterone levels and 11βHSD2 mRNA expression and activity in the whole kidney remain unchanged. High salt diet does not affect whole body Na+ and/or K+ balance and NCC activity is not reduced, but leads to a significant increase in diastolic blood pressure dipping in Nr3c1Pax8/LC1 mice. When high sodium treatment is followed by 48 h of darkness, NCC abundance is reduced in knockout mice although activity is not different. Our data show that upon Na+ restriction renal tubular GR-deficiency transiently affects Na+ handling and transport pathways. Overall, upon standard, low Na+ and high Na+ diet exposure Na+ and K+ balance is maintained as evidenced by normal plasma and urinary Na+ and K+ and aldosterone concentrations.

1 December 2011 in Atherosclerosis
Verified
Journal Article
Closed access
SVSofia N. Verouti
Sofia N. Verouti
EFElizabeth Fragopoulou
Elizabeth Fragopoulou
HKHaralabos C. Karantonis
Haralabos C. Karantonis
ADAndromaxi A. Dimitriou
Andromaxi A. Dimitriou
ATAlexandros D. Tselepis
Alexandros D. Tselepis
CDConstantinos A. Demopoulos
Constantinos A. Demopoulos

14 March 2013 in Nephron Experimental Nephrology
Verified
Journal Article
Closed access
SVSofia N. Verouti
Sofia N. Verouti
ETE.C. Tsilibary
E.C. Tsilibary
EFE. Fragopoulou
E. Fragopoulou
CIC. Iatrou
C. Iatrou
CDC.A. Demopoulos
C.A. Demopoulos
GDG.I. Drossopoulou
G.I. Drossopoulou
Background: Vitamin D is beneficial in human and experimental chronic kidney disease, the leading cause of which is diabetic nephropathy. Vitamin D through its receptor, VDR, provides renal protection in diabetic nephropathy, but limited data exist about its effect on podocytes. Renal podocytes form the main filtration barrier possessing a unique phenotype maintained by proteins including podocalyxin and nephrin, the expression of which is suppressed in pathological conditions. Methods: We used immortalized human podocytes (human glomerular epithelial cells, HGEC) to assess podocalyxin and nephrin expression after treatment with 1,25-dihydroxyvitamin D3 (calcitriol) and its analogue paricalcitol. The involvement of VDR was investigated by silencing with hVDR-siRNA and ChIP analysis. Results: HGEC exhibit high glucose-mediated downregulation of podocalyxin and nephrin, loss of which has been linked with loss of the permselective renal barrier and proteinuria. Calcitriol and paricalcitol reversed high glucose-induced decrease of nephrin and significantly enhanced podocalyxin expression in podocytes cultured in high glucose. HGEC express VDR and retinoid X receptor (RXR). In the presence of calcitriol and paricalcitol, VDR expression was upregulated and VDR colocalized with RXR in the nucleus. VDR knockdown abolished the protective action of calcitriol and paricalcitol on podocalyxin expression indicating that podocalyxin activation of expression is partly mediated by VDR. Furthermore, VDR specifically regulates podocalyxin expression by bounding to a site upstream of the podocalyxin promoter. Conclusion: Vitamin D analogues maintain and, furthermore, re-activate the expression of specialized components of podocytes including podocalyxin, hence they provide protection against loss of the permselective renal barrier, with molecular mechanisms elucidated herein.